TRAIL Protein (AA 118-281, Trimer) (His-DYKDDDDK Tag)

Catalog No. ABIN7275775

Product Details

Target: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Protein Type: Recombinant

Protein Characteristics: AA 118-281, Trimer

Origin: Human

Source: HEK-293 Cells

Purification tag / Conjugate: This TRAIL protein is labelled with His-DYKDDDDK Tag.

Purpose: Human TRAIL Trimer Protein

Sequence: Gly118-Gly281

Characteristics: Recombinant Human TRAIL Trimer Protein is expressed from HEK293 with His tag and Flag tag at the N-Terminus.It contains Gly118-Gly281.

Purity: > 95 % as determined by Tris-Bis PAGE,> 90 % as determined by HPLC

Sterility: 0.22 μm filtered

Endotoxin Level: Less than 1EU per μg by the LAL method.

Biological Activity Comment: Immobilized TRAIL Trimer, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 49.2ng/ml determined by ELISA. See testing image for detail.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Storage: -20 °C,-80 °C

Storage Comment: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Expiry Date: 12 months

Target Details

Target: TRAIL (TNFSF10) (Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))

Alternative Name: TRAIL (TNFSF10 Products)

Background: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents.

Molecular Weight: 60 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.

UniProt: P50591-1

Pathways: Apoptosis, Positive Regulation of Endopeptidase Activity